Last reviewed 2026-04-23 · How we verify

LF111 (drospirenone)

Drospirenone is a progestin that acts as a progesterone receptor agonist and aldosterone antagonist, used in hormonal contraceptive formulations.

Drospirenone is a progestin that acts as a progesterone receptor agonist and aldosterone antagonist, used in hormonal contraceptive formulations. Used for Oral contraception, Treatment of premenstrual dysphoric disorder (PMDD).

At a glance

Mechanism of action

Drospirenone binds to progesterone receptors in the hypothalamus and pituitary, suppressing the luteinizing hormone (LH) surge and inhibiting ovulation. It also possesses antimineralocorticoid activity, providing mild diuretic and potassium-sparing effects. In combination with ethinyl estradiol or estradiol, it is used for contraception and management of hormone-responsive conditions.

Approved indications

• Oral contraception
• Treatment of premenstrual dysphoric disorder (PMDD)

Common side effects

• Nausea
• Headache
• Breast tenderness
• Breakthrough bleeding
• Mood changes

Key clinical trials

• LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women (PHASE4)
• Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LF111 (drospirenone) CI brief — competitive landscape report
• LF111 (drospirenone) updates RSS · CI watch RSS
• Laboratories Leon Farma, S.A. portfolio CI